3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Myelodysplastic Syndromes
5
Recurrence
4
Leukemia, Myeloid, Acute
3
Leukemia
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Lung Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rubinstein-Taybi Syndrome
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Carcinoma, Transitional Cell
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
mocetinostat
×
Clear all
NCT02993991
2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1
Withdrawn